Short Interest in OncoGenex Pharmaceuticals Decreases By 45.7% (OGXI)
Shares of OncoGenex Pharmaceuticals (NASDAQ:OGXI) were the recipient of a significant decrease in short interest during the month of July. As of July 31st, there was short interest totalling 305,595 shares, a decrease of 45.7% from the July 15th total of 562,692 shares, American Banking News reports. Currently, 1.6% of the shares of the stock are short sold. Based on an average daily volume of 113,186 shares, the short-interest ratio is currently 2.7 days.
In other OncoGenex Pharmaceuticals news, CEO Scott Daniel Cormack sold 18,341 shares of OncoGenex Pharmaceuticals stock in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $3.17, for a total transaction of $58,140.97. The transaction was disclosed in a filing with the SEC, which is available at this link.
OncoGenex Pharmaceuticals (NASDAQ:OGXI) opened at 3.30 on Friday. OncoGenex Pharmaceuticals has a one year low of $2.86 and a one year high of $14.25. The stock has a 50-day moving average of $3.24 and a 200-day moving average of $7.01. The company’s market cap is $69.8 million.
OncoGenex Pharmaceuticals (NASDAQ:OGXI) last released its earnings data on Thursday, August 7th. The company reported ($0.47) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.55) by $0.08. Analysts expect that OncoGenex Pharmaceuticals will post $-1.75 EPS for the current fiscal year.
OncoGenex Pharmaceuticals, Inc (NASDAQ:OGXI) is a biopharmaceutical company engaged in the development and commercialization of new cancer therapies that address treatment resistance in cancer patients.
Receive News & Ratings for OncoGenex Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoGenex Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.